ZA922239B - Heterocyclic-cyclic amine derivatives. - Google Patents

Heterocyclic-cyclic amine derivatives.

Info

Publication number
ZA922239B
ZA922239B ZA922239A ZA922239A ZA922239B ZA 922239 B ZA922239 B ZA 922239B ZA 922239 A ZA922239 A ZA 922239A ZA 922239 A ZA922239 A ZA 922239A ZA 922239 B ZA922239 B ZA 922239B
Authority
ZA
South Africa
Prior art keywords
heterocyclic
cyclic amine
amine derivatives
compounds
formula
Prior art date
Application number
ZA922239A
Other languages
English (en)
Inventor
Anabella Villalobos
Arthur Adam Nagel
Yuhpyng Liang Chen
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of ZA922239B publication Critical patent/ZA922239B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Production Of Liquid Hydrocarbon Mixture For Refining Petroleum (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
ZA922239A 1991-03-28 1992-03-27 Heterocyclic-cyclic amine derivatives. ZA922239B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US67691891A 1991-03-28 1991-03-28

Publications (1)

Publication Number Publication Date
ZA922239B true ZA922239B (en) 1993-09-27

Family

ID=24716559

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA922239A ZA922239B (en) 1991-03-28 1992-03-27 Heterocyclic-cyclic amine derivatives.

Country Status (29)

Country Link
EP (1) EP0646115B1 (fr)
JP (3) JP2659107B2 (fr)
KR (1) KR0179054B1 (fr)
CN (1) CN1044242C (fr)
AT (1) ATE231505T1 (fr)
AU (2) AU658194B2 (fr)
BR (1) BR9205811A (fr)
CA (2) CA2195129C (fr)
CZ (1) CZ289756B6 (fr)
DE (1) DE69232907T2 (fr)
DK (1) DK0646115T3 (fr)
EG (1) EG20281A (fr)
ES (1) ES2188584T3 (fr)
FI (1) FI934223A0 (fr)
HU (1) HU225047B1 (fr)
IE (1) IE920980A1 (fr)
IL (3) IL116122A (fr)
MX (1) MX9201419A (fr)
MY (1) MY108885A (fr)
NO (1) NO304071B1 (fr)
NZ (3) NZ248946A (fr)
PL (3) PL171915B1 (fr)
PT (1) PT100300B (fr)
RU (1) RU2119920C1 (fr)
SG (1) SG49055A1 (fr)
UA (1) UA45944C2 (fr)
WO (1) WO1992017475A1 (fr)
YU (1) YU31392A (fr)
ZA (1) ZA922239B (fr)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5750542A (en) 1993-09-28 1998-05-12 Pfizer Benzisoxazole and benzisothizole derivatives as cholinesterase inhibitors
CA2116117A1 (fr) * 1991-08-22 1993-03-04 Hiroyuki Sueoka Compose de type benzisoxazole et son utilisation
EP0535496A1 (fr) * 1991-09-25 1993-04-07 Hoechst-Roussel Pharmaceuticals Incorporated (1-Indanon-2-yl)méthylpipéridines, produits intermédiaires et procédé pour leur préparation et leur utilisation comme médicaments
DK0669920T3 (da) * 1992-11-23 2003-05-26 Aventis Pharma Inc Substituerede 3-(aminoalkylamino)-1,2-benzisoxazoler og beslægtede forbindelser
US5494908A (en) * 1992-11-23 1996-02-27 Hoechst-Roussel Pharmaceutical Incorporated Substituted 3-(aminoalkylamino)-1,2-benzisoxazoles and related compounds
GB9305623D0 (en) * 1993-03-18 1993-05-05 Merck Sharp & Dohme Therapeutic agents
CA2200607C (fr) * 1994-10-26 2003-03-18 Pfizer Inc. Procedes et intermediaires pour preparer la 5,7-dihydro-3-[2{1-benzylpiperidin-4-yl}ethyl]-6h-pyrrolo-[4,5-f]-1,2-benzisoxazol-6-one
EP0809642A1 (fr) * 1995-02-15 1997-12-03 PHARMACIA & UPJOHN COMPANY Imidazo 1,2-a]pyridines pour le traitement du snc et de cardiopathologies
JP3884477B2 (ja) * 1995-03-22 2007-02-21 大正製薬株式会社 チアゾール誘導体
JP3122469B2 (ja) * 1995-06-06 2001-01-09 ヘキスト・マリオン・ルセル・インコーポレイテツド 抗精神病剤としてのピリジンイミニル−１，２−ベイゾイソオキサゾール類及び−ベンゾイソチアゾール類
JPH09124643A (ja) * 1995-08-14 1997-05-13 Bristol Myers Squibb Co 抗うつ作用を有する１−アリールアルキル−４−（アルコキシピリジニル）−又は４−（アルコキシピリミジニル）ピペラジン誘導体
US5916902A (en) * 1995-09-13 1999-06-29 Pfizer Inc. Processes and intermediates for preparing 5, 7-dihydro-3- 2-(1-benzylpiperidin-4-yl)ethyl-!6H-pyrrolo- 4, 5-F!-1, 2-benzisoxazol-6-one
AU7319096A (en) * 1995-11-02 1997-05-22 Merck Sharp & Dohme Limited Bicyclic heteroaryl-alkylene-(homo)piperazinones and thione analogues thereof, their preparation and their use as selective agonists of 5-ht1-like receptors
FR2751412B3 (fr) * 1996-07-17 1998-09-25 Valbiofrance Methodes de diagnostic in vitro de maladies neurodegeneratives et trousses pour la mise en oeuvre de ces methodes
US6013654A (en) * 1997-08-14 2000-01-11 Pharmacia & Upjohn Company Imidazo[1,2-A]pyridines for the treatment of CNS and cardiac diseases
EP0976404A3 (fr) * 1998-07-30 2001-06-27 Pfizer Products Inc. Compositions pharmaceutiques pour la prévention et la therapie de troubles cognitifes chez les mammifères
KR100648869B1 (ko) 1998-09-30 2007-02-28 다케다 야쿠힌 고교 가부시키가이샤 방광 배출력 개선제
US6951873B1 (en) 1999-04-27 2005-10-04 Pfizer Inc. Methods for treating age-related behavioral disorders in companion animals
EP1050303A3 (fr) * 1999-04-27 2003-01-15 Pfizer Products Inc. Methodes et compositions pour le traitement des troubles du comportement liées à l'age des animaux de compagnie
AU767726B2 (en) * 1999-04-30 2003-11-20 Pfizer Products Inc. Radiotracers for in vivo study of acetylcholinesterase and Alzheimer's disease
GB9914486D0 (en) 1999-06-21 1999-08-18 Smithkline Beecham Plc Medicaments
GB9917408D0 (en) 1999-07-23 1999-09-22 Smithkline Beecham Plc Compounds
GB9917406D0 (en) 1999-07-23 1999-09-22 Smithkline Beecham Plc Compounds
US7091218B1 (en) 1999-09-01 2006-08-15 Eisai Co., Ltd. 4-substituted piperidine compound
DE60139781D1 (de) 2000-06-21 2009-10-15 Eisai R&D Man Co Ltd 4-substituierte piperidinverbindung
EP1609783A1 (fr) * 2004-06-17 2005-12-28 Neuropharma S.A.U. Composes marines bloquant les canaux calciques pur le traitement de la maladie de alzheimer
DE102005038947A1 (de) * 2005-05-18 2006-11-30 Grünenthal GmbH Substituierte Benzo[d]isoxazol-3-yl-amin-Verbindungen und deren Verwendung in Arzneimitteln
JP2008545008A (ja) * 2005-06-30 2008-12-11 プロシディオン・リミテッド Ｇｐｃｒアゴニスト
GB0519879D0 (en) 2005-09-30 2005-11-09 Astrazeneca Ab Chemical process
WO2007126041A1 (fr) 2006-04-28 2007-11-08 Eisai R & D Management Co., Ltd. Compose benzisoxazole
AU2008263206A1 (en) 2007-06-01 2008-12-18 Schering Corporation Gamma secretase modulators
US8008327B2 (en) 2008-04-29 2011-08-30 Boehringer Ingelheim International Gmbh Indazole compounds as CCR1 receptor antagonists
US8293917B2 (en) 2008-05-06 2012-10-23 Boehringer Ingelheim International Gmbh Pyrazole compounds as CCR1 antagonists
NZ591115A (en) 2008-09-26 2012-10-26 Boehringer Ingelheim Int Azaindazole compounds as ccr1 receptor antagonists
MX2011005905A (es) * 2008-12-12 2011-06-20 Actelion Pharmaceuticals Ltd Derivados de 5-amino-2-(1-hidroxi-etil)-tetrahidropirano.
IN2012DN03449A (fr) 2009-10-21 2015-10-23 Boehringer Ingelheim Int
WO2011056440A1 (fr) 2009-10-27 2011-05-12 Boehringer Ingelheim International Gmbh Composés hétérocycliques utilisés en tant qu'antagonistes des récepteurs ccr1
CA2789014C (fr) 2010-02-09 2019-01-15 Michela Gallagher Procedes et compositions pour ameliorer la fonction cognitive
US8871786B2 (en) 2010-04-30 2014-10-28 Boehringer Ingelheim International Gmbh Azaindazole amide compounds as CCR1 receptor antagonists
US8546442B2 (en) 2010-12-23 2013-10-01 Boehringer Ingelheim International Gmbh Pyrazolopiperidine compounds as CCR1 receptor antagonists
WO2014078568A1 (fr) 2012-11-14 2014-05-22 The Johns Hopkins University Méthodes et compositions pour le traitement de la schizophrénie
US10179779B2 (en) * 2012-11-21 2019-01-15 Raqualia Pharma Inc. Polymorph forms
US11160785B2 (en) 2013-03-15 2021-11-02 Agenebio Inc. Methods and compositions for improving cognitive function
EP3827820A1 (fr) 2013-03-15 2021-06-02 The Johns Hopkins University Brivaracetam pour améliorer la fonction cognitive
BR112017025031B1 (pt) 2015-05-22 2023-03-21 Agenebio, Inc Composições farmacêuticas de liberação prolongada de levetiracetam
RU2638155C1 (ru) * 2016-02-29 2017-12-12 Общество С Ограниченной Ответственностью "Сай Фарма" Производные бензо[d]изоксазола и их применение
JP2024529068A (ja) * 2021-08-10 2024-08-01 江蘇恒瑞医薬股▲ふん▼有限公司 スルファミド誘導体、その調製方法及びその医薬的使用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3488353A (en) * 1967-05-29 1970-01-06 Sterling Drug Inc New 1-((2-azaindolyl)-lower-alkyl) 4-substituted-piperazines
JPS51136666A (en) * 1975-05-19 1976-11-26 Dainippon Pharmaceut Co Ltd Process for preparing 3-aminoalkyl-1,2-benzisoxazole derivatives.
US4396770A (en) * 1982-04-09 1983-08-02 Hoechst-Roussel Pharmaceuticals Inc. 1-[3-(6-Fluoro-1,2-benzisoxazol-3-yl)propyl]-4-hydroxy-4-phenylpiperidines
IL66866A (en) * 1982-04-09 1987-08-31 Hoechst Roussel Pharma 1-(3-(6-fluoro-1,2-benzisoxazol-3-yl)propyl)-4-(substituted)-piperazines and-piperidines,a process for the preparation thereof,and pharmaceutical compositions containing them
US4489075A (en) * 1982-05-15 1984-12-18 Pfizer Inc. Cyclic sulfonamidoalkyl substituted 4-piperidinoquinazoline cardiac stimulants
PH22302A (en) * 1985-02-11 1988-07-22 Fujisawa Pharmaceutical Co Piperidine compounds
DK623586A (da) * 1985-12-27 1987-06-28 Eisai Co Ltd Piperidinderivater eller salte deraf og farmaceutiske kompositioner indeholdende forbindelserne
JPS63234065A (ja) * 1987-03-23 1988-09-29 Mitsubishi Rayon Co Ltd 包接能を有する高分子組成物
JPH0657707B2 (ja) * 1987-05-25 1994-08-03 吉富製薬株式会社 ピペリジン化合物
FI95572C (fi) * 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
US4980365A (en) * 1987-07-13 1990-12-25 Hoechst-Roussel Pharmaceuticals Inc. N-substituted-5,6-dimethoxy-1,2-benzisoxazole-3-propanamine and related compounds as analgesic and hypotensive agents
EP0330353B1 (fr) * 1988-02-19 1993-04-07 Eli Lilly And Company Composés de tétrazole comme antagonistes de récepteurs excitatifs d'aminoacides
JPH0283375A (ja) * 1988-09-21 1990-03-23 Dainippon Pharmaceut Co Ltd ２−置換ピペラジニル−２−（１，２−ベンズイソキサゾール−３−イル）酢酸誘導体
FR2654104B1 (fr) * 1989-11-07 1992-01-03 Adir Nouveaux derives du 1,2-benzisoxazole, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
DK0641320T3 (da) * 1991-04-17 2001-08-20 Upjohn Co Substituerede (S)-3-phenylpiperidinderivater, deres fremstilling og deres anvendelse som dopaminautoreceptorantagonister

Also Published As

Publication number Publication date
PL171914B1 (pl) 1997-06-30
NZ248946A (en) 1995-04-27
PL170567B1 (pl) 1997-01-31
DK0646115T3 (da) 2003-04-22
RU2119920C1 (ru) 1998-10-10
AU1878292A (en) 1992-11-02
EG20281A (en) 1998-07-30
JP2000154185A (ja) 2000-06-06
WO1992017475A1 (fr) 1992-10-15
IL101327A0 (en) 1992-11-15
SG49055A1 (en) 1998-05-18
IL116122A0 (en) 1996-01-31
CA2107105C (fr) 2003-10-07
NO933445L (no) 1993-09-27
NZ242151A (en) 1994-10-26
CZ289756B6 (cs) 2002-04-17
KR0179054B1 (en) 1999-03-20
JP2659107B2 (ja) 1997-09-30
IL116122A (en) 1998-10-30
HU9302733D0 (en) 1993-12-28
YU31392A (sh) 1994-12-28
CN1044242C (zh) 1999-07-21
JPH06500794A (ja) 1994-01-27
CA2195129C (fr) 2002-09-10
UA45944C2 (uk) 2002-05-15
EP0646115B1 (fr) 2003-01-22
CZ395892A3 (en) 1994-04-13
IE920980A1 (en) 1992-10-07
JP3051076B2 (ja) 2000-06-12
NZ250987A (en) 1997-06-24
MX9201419A (es) 1992-10-01
PT100300B (pt) 1999-09-30
AU2178895A (en) 1995-09-07
NO304071B1 (no) 1998-10-19
FI934223A (fi) 1993-09-27
HUT68357A (en) 1995-06-28
AU674477B2 (en) 1996-12-19
CN1065267A (zh) 1992-10-14
DE69232907D1 (de) 2003-02-27
DE69232907T2 (de) 2003-05-15
FI934223A0 (fi) 1993-09-27
PL171915B1 (pl) 1997-06-30
MY108885A (en) 1996-11-30
ES2188584T3 (es) 2003-07-01
JPH10158264A (ja) 1998-06-16
EP0646115A1 (fr) 1995-04-05
BR9205811A (pt) 1994-06-28
CA2195129A1 (fr) 1992-09-29
CA2107105A1 (fr) 1992-09-29
AU658194B2 (en) 1995-04-06
NO933445D0 (no) 1993-09-27
IL101327A (en) 1998-06-15
PT100300A (pt) 1993-08-31
ATE231505T1 (de) 2003-02-15
HU225047B1 (en) 2006-05-29

Similar Documents

Publication Publication Date Title
KR0179054B1 (en) Heterocyclic-cyclic amine derivatives
TWI224595B (en) New benzazepine derivatives, drugs containing these and use of the same for producing drugs
GB9002922D0 (en) 17 beta-substituted-4-aza-5 alpha-androstan-3-one derivatives and process for their preparation
NO944928D0 (no) Fremgangsmåter for inhibering av Alzheimers sykdom
HU9301362D0 (en) Method for producing 4-aryl-piperazines and 4-aryl-piperidines
MY132671A (en) Substituted 6,6-hetero-bicyclic derivatives
FI96204C (fi) Menetelmä terapeuttisesti käyttökelpoisten heterosyklisten yhdisteiden valmistamiseksi
CA2189007A1 (fr) Methodes pour preparer des formes anhydres et hydratees de derives antihistaminiques de la piperidine; leurs formes polymorphes et pseudomorphes
ATE123024T1 (de) 4-aminopyridinderivate.
ZA914133B (en) Preparation of substituted piperidines
BG105247A (en) N-substituted azabicycloheptane derivatives, production and use thereof
ATE63309T1 (de) 2,3-dihydro-2-oxo-3-benzofuranylessigs|urederivate und diese enthaltende arzneimittel.
PH24501A (en) Substituted 3-phenyl-7h-thiazolo(3,2-b)(1,2,4)triazin-7-ones
IL140919A0 (en) N-substituted azabicycloheptane derivatives, production and use thereof